



attana

life science and diagnostics

Information about Attana's presentation at Stora Aktiedagen on December 1 at 10.30

On Wednesday December 1 at 10.30, Attana will participate in Aktiespararna's Stora Aktiedag where Attana's CEO, Teodor Aastrup, will give a 20-minute-long presentation followed by a 10-minute-long Q&A.

The presentation will be held in Swedish and primarily focus on Attana's plan going forward, both short- and long-term within both of its business units – Life Science and Diagnostics.

Preliminary outline:

1. *Attana in short*
2. *Business units*
 - a. *Attana Life Science*
 - b. *Attana Diagnostics*
3. *Macro impacts*
4. *Action plan 2022-2030*
 - a. *Corporate development*
 - b. *Sales & marketing*
 - c. *Product development*
 - d. *M&A*

The event is live streamed and can be viewed on Aktiespararna's Youtube channel. Listeners are welcome to send questions for Attana to the moderator via sms to 0793479845

When: Wednesday, December 1 at 10.30

Where: Live streamed from Hotel Sheraton, can be accessed through this [link](#)

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of *in vitro* characterization of molecular interactions mimicking *in vivo* conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary *in vitro* diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com